H.C. Wainwright & Co., LLC

H.C. Wainwright is pleased to announce its #1 ranking by transaction volume for the third quarter of 2024, marking an impressive 38 consecutive quarters of holding this top position. According to PlacementTracker's Market League Tables, H.C. Wainwright led both the PIPE and Private Placement Markets and At-the-Market (ATM) Offerings, representing 84 and 52 transactions, respectively. Since the beginning of 2024, we have executed approximately 240 transactions, totaling over $10.78 billion in value. We extend our sincerest gratitude to our clients and partners for their continued trust and support. Learn more about H.C. Wainwright and see all of our transactions online at www.hcwco.com/transactions.

We are pleased to have served as the Exclusive Agent for Senseonics Holdings' $16 Million Follow-On offering. Learn more about H.C. Wainwright and see all of our transactions online at www.hcwco.com/transactions

We are excited to announce our upcoming HCW @ Home with Cardiol Therapeutics Inc. (CRDL) on October 29 at 12pm EST, moderated by Research Analyst Vernon Bernardino. Join us as Cardiol President and Chief Executive Officer, David Elsley, along with Chief Medical Officer and Head of Research and Development, Andrew Hamer, discuss the latest advancements in the company’s pipeline and their strategic vision for 2024 and beyond. Will you be tuning in next Tuesday? Register now at https://lnkd.in/gg58a2ny

Voyager Therapeutics, Inc. (NASDAQ: VYGR) will present at our HCW @ Home virtual fireside chat on October 23 from 10am to 11am EST, featuring Voyager’s President and Chief Executive Officer Alfred Sandrock, MD, PhD; Chief Medical Officer Toby Ferguson, MD, PhD; Chief Scientific Officer Todd Carter, PhD; and Chief Financial Officer Nathan Jorgensen, PhD, MBA. Moderated by Research Analyst Patrick Trucchio, the discussion will cover recent progress in Voyager’s pipeline across multiple neurological disease indications. Reserve your spot today: https://lnkd.in/e9TVFkpm

Mark your calendars for next Tuesday, October 22, from 10am to 11am EST when Immunocore (NASDAQ: IMCR) will be featured in our upcoming HCW @ Home. Join Lucy Dorrell, MD, MBBS, FRCP, Head of Infectious Diseases at Immunocore, along with covering Research Analyst Patrick Trucchio, for a virtual fireside chat where they’ll delve into the latest advancements in Immunocore’s HIV ImmTAV platform within their infectious disease pipeline. Register now: https://lnkd.in/gDjwmNSM

We are pleased to have served as Lead Manager for Crinetics Pharmaceuticals’ $500 Million Upsized Follow-On offering. Learn more about H.C. Wainwright and see all of our transactions online at www.hcwco.com/transactions

We extend our gratitude to all who participated in our annual Viral Hepatitis Conference yesterday. Our agenda featured esteemed KOLs, insightful company presentations, and enriching fireside chats—all of which contributed to a meaningful exchange of ideas surrounding the viral hepatitis treatment landscape. To be a part of future conferences, please visit www.hcwevents.com.

A huge thank you to all who participated at our MASH Investor Conference yesterday where we delved into the current landscape and the future of the Metabolic Dysfunction-Associated Steatohepatitis therapeutic space through various discussions featuring KOLs, company presentations, fireside chats, and meetings. Your active participation and insights truly enriched our conversations, making the event both productive and inspiring. We look forward to continuing the dialogue together! Check out our upcoming therapeutics conferences at www.hcwevents.com

Another Biotech on Tap in the books! Thank you to all attendees who joined us this week at the 5th Annual Biotech on Tap at Oktoberfest. It was an insightful and network filled week in Munich discussing the U.S. and EU markets, M&A, IPOs, Artificial Intelligence, and the Biotech sector.   A special shout to our co-host Goodwin as well as our sponsors CFGI, EY, NautaDutilh, and Toppan Merrill. We're in the process of planning Biotech on Tap 2025! If you have any ideas or would like an invitation, please reach out to Thomas Hoffmann, Dirk Gallowsky, or Robert Puopolo. Prost!

We invite you to join us on October 8th at the 5th Annual Viral Hepatitis Virtual Conference to engage in an in-depth exploration of the various viruses responsible for hepatitis, along with discussions on emerging technologies in the field. Join esteemed industry thought leaders as they share their insights and emerging advancements, contributing to combating viral hepatitis.   For more information and registration, visit https://lnkd.in/ehDKx6xJ